Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
Sucampo Pharmaceuticals, Inc. (Sucampo), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a patent for VTS-270, a novel and well-characterized 2-hydroxypropyl-beta-cyclodextrin (HPβCD) product, under investigation as an intrathecally administered treatment for Niemann-Pick Disease Type C1 (NPC-1). Sucampo Pharmaceuticals, Inc. (Sucampo), a global biopharmaceutical company, today announced that [...]